Portage Biotech Inc
NASDAQ:ATON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China Castson 81 Finance Co Ltd
OTC:CNCSF
|
HK |
Portage Biotech Inc
Research & Development
Portage Biotech Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Portage Biotech Inc
NASDAQ:ATON
|
Research & Development
-$3.7m
|
CAGR 3-Years
20%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
Portage Biotech Inc
Glance View
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
See Also
What is Portage Biotech Inc's Research & Development?
Research & Development
-3.7m
USD
Based on the financial report for Sep 30, 2025, Portage Biotech Inc's Research & Development amounts to -3.7m USD.
What is Portage Biotech Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-1%
Over the last year, the Research & Development growth was 45%. The average annual Research & Development growth rates for Portage Biotech Inc have been 20% over the past three years , 4% over the past five years , and -1% over the past ten years .
